| P2093 | author name string | Xiaoqun Dong | |
| | Jack R Wands | |
| | Rolf I Carlson | |
| | Michael S Lebowitz | |
| | Zhi-Gang Jiang | |
| | Hossein Ghanbari | |
| | Yanmei Zhou | |
| | Xuewei Bai | |
| | Kosuke Ogawa | |
| | Katsuya Nagaoka | |
| | Songhua Zhang | |
| | Steve Fuller | |
| P2860 | cites work | Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma | Q24562001 |
| | Antibody-drug conjugates--an emerging class of cancer treatment | Q26770312 |
| | Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer | Q27013852 |
| | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 |
| | Notch signaling: cell fate control and signal integration in development | Q27861061 |
| | Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation | Q28139424 |
| | Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) β-hydroxylase suppress migration of cholangiocarcinoma cells | Q28201030 |
| | Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility | Q28214662 |
| | Prognostic value of humbug gene overexpression in stage II colon cancer | Q33259349 |
| | Isolation and characterization of human antibodies targeting human aspartyl (asparaginyl) beta-hydroxylase | Q33323345 |
| | U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. | Q33403209 |
| | Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma | Q33944587 |
| | A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma | Q34250364 |
| | Aspartate β-Hydroxylase expression promotes a malignant pancreatic cellular phenotype | Q35176052 |
| | Immunization with aspartate-β-hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma | Q35624314 |
| | Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma | Q35894880 |
| | Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression. | Q35949450 |
| | Activation of signal transduction pathways during hepatic oncogenesis | Q36386273 |
| | Aspartate β-hydroxylase modulates cellular senescence through glycogen synthase kinase 3β in hepatocellular carcinoma | Q36723189 |
| | LRH1 as a driving factor in pancreatic cancer growth | Q37623867 |
| | Antibody Drug Conjugates for Cancer Therapy | Q38640861 |
| | Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. | Q38648690 |
| | The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer | Q38733994 |
| | Antibody-drug conjugates: recent advances in conjugation and linker chemistries. | Q38981429 |
| | Targeted therapies for gastric cancer: failures and hopes from clinical trials | Q41340207 |
| | Tumor measurement in the nude mouse | Q41355093 |
| | Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome | Q43005656 |
| | Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. | Q45928785 |
| | Overexpression of HER2/neu oncogene in human pancreatic carcinoma | Q46060370 |
| | Determination of subcutaneous tumor size in athymic (nude) mice | Q46296687 |
| | Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. | Q51141565 |
| | A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. | Q53280066 |
| | Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. | Q54398738 |
| | Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. | Q54590341 |
| | Pancreatic Adenocarcinoma | Q55880513 |
| | Quantification of histochemical staining by color deconvolution | Q74448733 |
| | Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma | Q80998517 |
| | Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma | Q81073375 |
| | Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? | Q84961795 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P921 | main subject | invasive ductal carcinoma | Q1671685 |
| | pancreatic ductal carcinoma | Q8263002 |
| | pancreatic ductal adenocarcinoma | Q18555956 |
| P304 | page(s) | 87-98 | |
| P577 | publication date | 2019-02-12 | |
| P1433 | published in | Cancer Letters | Q326372 |
| P1476 | title | Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma | |
| P478 | volume | 449 | |